Sanofi (SNY) — Q3 2026 Earnings Preview
Key Takeaways and Preview Summary
- Consensus expects continued double-digit sales and EPS growth in Q3 2026, but at a slower pace than H1 due to tougher comps and annualization of recent launches.
- Management recently upgraded FY 2026 guidance to ~10% sales growth and business EPS growing slightly faster than sales.
- Dupixent remains the primary growth driver, with Q2 2026 sales exceeding €5B (+37% YoY), but management has flagged growth moderation in H2 as new indications annualize and comparables toughen.
- Recent alliance expansion with Regeneron positions Sanofi for long-term leadership in immunology, but near-term focus is on sustaining momentum and managing Dupixent LOE risk.
- Key investor focus: sustainability of volume-driven growth, gross-to-net dynamics (especially in the U.S.), progress on pipeline rationalization, and clarity on BD/M&A execution.
- Q3 2025 was a tough comparable (+13% sales growth YoY), so Q3 2026 faces a high base.
Most Important Factors to Watch in Q3 2026
| Factor | Why It Matters | What to Watch |
|---|---|---|
| Dupixent Growth & Mix | Largest product, upgraded 2030 ambition to €25B; Q2 2026 +37% YoY | Volume vs. price/mix, U.S. GTN trends, impact of new indications, signs of growth moderation |
| Launch Portfolio Performance | Launches now 13% of sales, up >60% YoY in Q2 | ALTUVIIIO, Ayvakit, Sarclisa, Heplisav-B, Beyfortus: sequential growth, geographic expansion, market share gains |
| Vaccines Segment | Q2 2026 -5% YoY, guidance for slightly negative FY26 growth | Beyfortus and Heplisav-B offsetting flu headwinds, U.S. VCR trends, FX impact |
| Margin Progression | Q2 2026 gross margin +3.7 pts YoY (ex-one-offs +1.7 pts); BOI margin +3.8 pts | Underlying margin expansion, cost discipline, OpEx leverage, impact of one-offs |
| Guidance/Outlook | FY26 sales growth upgraded to ~10%, EPS to grow slightly faster | Any change to full-year outlook, color on H2 growth moderation, 2030 ambitions reaffirmed? |
| Pipeline & BD/M&A | Recent pipeline rationalization, alliance expansion with Regeneron | Updates on late-stage pipeline, further pruning, BD/M&A progress, capital allocation priorities |
| Dupixent LOE Risk | Expanded Regeneron alliance, ongoing patent defense | Management commentary on LOE timing, confidence in extending exclusivity, impact on future launches |
Quarterly Financial Snapshot — Actuals and Consensus
Quarterly Results (EUR Millions)
| Quarter | Revenue | Gross Profit Margin (%) | EBITDA | Net Income | EPS (GAAP) |
|---|---|---|---|---|---|
| Q2 2026 (cons.) | 12,217 | 78.1 | 3,471 | 2,534 | 0.58 |
| Q1 2026 (act.) | 11,847 | 77.6 | 3,338 | 2,550 | 1.89 |
| Q4 2025 (act.) | 12,978 | 74.0 | 2,960 | 2,094 | 1.05 |
| Q3 2025 (act.) | 14,466 | 76.2 | 5,173 | 3,821 | 2.76 |
| Q2 2025 (act.) | 11,763 | 75.6 | 3,066 | 2,298 | 4.41 |
Note: Q2 2026 is consensus; prior quarters are actuals.
Annual Results and Guidance
| Fiscal Year | Revenue | Gross Profit Margin (%) | EBITDA | Net Income | EPS (GAAP) | Business EPS Guidance | Sales Growth Guidance |
|---|---|---|---|---|---|---|---|
| 2026 (cons.) | 53,469 | 75.6 | 16,529 | 11,564 | 7.05 | EPS to grow slightly faster than sales | ~10% (upgraded) |
| 2025 (act.) | 50,762 | 74.9 | 15,554 | 11,038 | 7.83 | 12.2% (actual) | 9.9% (actual) |
| 2024 (act.) | 45,141 | 75.7 | 13,703 | 9,455 | 6.09 |
Q3 2025 — Prior Year Comparison
- Q3 2025 revenue: €14,466M (+13.3% YoY)
- Business EPS: +26.7% YoY
- Dupixent: €4.2B in Q4 2025, €15.7B FY25 (+>30% YoY patients)
- Launches: €5.7B FY25 (+34% YoY)
- Vaccines: €7.9B FY25, Beyfortus €1.8B (+9.5% YoY)
- Gross margin: 77.5% FY25 (+1.8 pts YoY)
- BOI margin: 27.8% FY25
Q3 2025 was a strong quarter with double-digit growth across key metrics, setting a high base for Q3 2026.
Guidance and Management Commentary
FY 2026 Guidance (as of Q2 2026)
| Metric | Guidance (FY 2026) | Context Notes |
|---|---|---|
| Sales Growth | ~10% at constant FX (upgraded) | Upgraded from "high single digit" after strong H1; H2 expected to moderate due to tougher comps |
| Business EPS Growth | Slightly faster than sales | Margin expansion, cost discipline, offsetting end of Regeneron R&D reimbursement with Amvuttra royalties |
| Vaccine Sales Growth | Slightly negative | Mainly due to flu headwinds and U.S. VCR trends |
| Capital Gains | ~€400M from divestments | Medley divestment closing expected end of 2026 |
| Tax Rate | ~21% | Reflects non-deductibility of certain impairments |
| BOI Impact (Regeneron/Amvuttra) | Net neutral in 2026, -€200M in 2027 | Amvuttra royalties offsetting Regeneron R&D reimbursement step-down |
Management Commentary Highlights
- On H2 2026: "We anticipate some deceleration of our sales growth. Indeed, we will lap in H2 against a strong sales momentum last year from Dupixent's new indication as well as the consolidation of Ayvakit, which began in July 2025."
- On Dupixent: "We anticipate the growth rate to moderate in the second half of the year as newly launched indications annualize and comparables become tougher."
- On Launches: "Looking ahead, we have additional launches for these medicines and vaccines in new geographies, and thus, we expect this portfolio to continue driving meaningful growth."
- On Vaccines: "We expect vaccine sales growth to be slightly negative in 2026, mainly crystallizing in H2 due to the usual seasonality of this business."
- On Margins: "Our gross margin increased by 3.7 percentage points... underlying gross margin was around 1.7 percentage points, driven by favorable product mix and efficiency."
- On BD/M&A: "It is also absolutely imperative that we intensify our business development and M&A activity in a disciplined way to enhance our mid- and long-term growth prospects."
- On Regeneron Alliance: "This agreement brings a stronger and more durable framework for our alliance, clearer governance, greater transparency and the resolution of the litigation between our companies."
What to Watch for in Q3 2026 Results
- Dupixent: Is volume-driven growth holding up? Any signs of price/mix pressure or GTN headwinds in the U.S.? Are new indications (COPD, CSU, BP) sustaining momentum?
- Launch Portfolio: Are ALTUVIIIO, Ayvakit, Sarclisa, Heplisav-B, and Beyfortus continuing to deliver >40% YoY growth? Any new launches or geographic expansions?
- Vaccines: Is Beyfortus offsetting flu headwinds? Any further impact from U.S. vaccination coverage rates or FX?
- Margins: Is underlying gross margin expansion sustained? Any further one-off benefits or normalization?
- Guidance: Does management maintain or further upgrade FY26 guidance? Any new color on 2030 ambitions or Dupixent LOE risk mitigation?
- Pipeline/BD: Any new pipeline prioritization or pruning? Progress on late-stage assets (frexalimab, riliprubart, efdoralprin alfa)? Any BD/M&A announcements?
- Regeneron Alliance: Any updates on next-generation Type 2 assets, alliance economics, or integration of new programs?
Conclusion
Sanofi enters Q3 2026 earnings off a very strong H1 and a high Q3 2025 comparable. The company has upgraded its FY26 guidance after robust volume-driven growth, especially in Dupixent and its launch portfolio. However, management has flagged that H2 growth will moderate due to tougher comps and annualization of recent launches. Investors should focus on the sustainability of Dupixent's growth, margin progression, vaccines performance, and any signals on pipeline execution and BD/M&A. The expanded Regeneron alliance provides long-term strategic clarity, but near-term delivery and execution remain key.
Reference Tables
Quarterly Revenue and Growth (EUR Millions)
| Quarter | Revenue | YoY Growth |
|---|---|---|
| Q2 2026 (cons.) | 12,217 | |
| Q1 2026 (act.) | 11,847 | |
| Q4 2025 (act.) | 12,978 | |
| Q3 2025 (act.) | 14,466 | +13.3% |
| Q2 2025 (act.) | 11,763 |
FY Revenue and Guidance (EUR Millions)
| Fiscal Year | Revenue | YoY Growth | Guidance (Sales Growth) |
|---|---|---|---|
| 2026 (cons.) | 53,469 | ~10% (upgraded) | |
| 2025 (act.) | 50,762 | +9.9% | High single digit (prior) |
| 2024 (act.) | 45,141 |
Sanofi reports Q3 2026 results against a high base, with investor focus on Dupixent’s growth trajectory, launch portfolio momentum, margin expansion, and execution on pipeline and BD/M&A. Guidance has been upgraded, but H2 growth is expected to moderate.
